The formation of blood clots is mediated by an intricate and dynamic interplay between platelets, blood clotting proteins, and small molecules. While rapid clot formation is essential for stopping blood loss at wound sites, uncontrolled blood clotting can evolve into thrombosis, causing organ failure and even death if left untreated. In order to better understand the underlying complex biochemistry of…
Read More

Zucara Therapeutics Announces New Board Member

Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Dr. Claude Piché has joined its Board of Directors. As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the company from start up through to completion of phase III clinical studies, ultimately…
Read More
Mutations in genes encoding epigenetic regulators as well as mutations in the histones they modify are increasingly recognized as drivers of transformation. Mutations in DNA methylation regulators have been identified as frequent early events in the generation of acute myeloid leukemia (AML) clones and are also found at high frequency in expanded, but apparently otherwise normal clones of blood cells in older people.
Read More

MSFHR Funds 53 Exceptional Health Researchers

MSFHR has announced 53 funding-award recipients (20 Scholars and 33 Research Trainees) from across the lower mainland, Prince George, Kelowna and Victoria. These award recipients, selected from a highly competitive pool of applicants, represent a bright future for health research in British Columbia. “We are thrilled that with the support of our award partners we are able to offer funding…
Read More

InMed Signs R&D Agreement with ATERA

 InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce it has entered into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models.  Under the terms of the agreement, ATERA will develop 3D human skin models of…
Read More
KCNQ5 is a highly conserved gene encoding an important channel for neuronal function; it is widely expressed in the brain and generates M-type current. Exome sequencing identified de novo heterozygous missense mutations in four probands with intellectual disability, abnormal neurological findings, and treatment-resistant epilepsy (in two of four). Comprehensive analysis of this potassium channel for the four variants expressed in…
Read More
Dr. Davide Pellacani is a postdoctoral fellow in the lab of Dr. Connie Eaves at the Terry Fox Research Institute. Approaching the end of his postdoc, Dr. Pellacani’s research has evolved throughout his career to include the merging of stem cell biology, epigenetics, bioinformatics, and cancer research. We sat down with Dr. Pellacani to discuss some of his current projects…
Read More
The news of a breakthrough cancer treatment that reprograms a patient’s DNA has refocused attention on similar research being done in B.C. 12 year old Emily Whitehead is alive today because of experimental cancer treatment that put her leukemia into remission when nothing else could. It’s called CAR-T therapy developed in the United States. Now the BC Cancer Agency is…
Read More

Feature Researcher: Alexander G. Beristain

Alexander G. Beristain is an Assistant Professor in the Division of Maternal Fetal Medicine. He received his Ph.D. (Reproductive and Developmental Sciences) from UBC Dept of OBGYN in 2007, and completed a postdoctoral fellowship with Dr. Rama Khokha at the Ontario Cancer Institute in 2012. He holds a New Investigator research grant from Sick Kids Foundation and John R Evans Leaders…
Read More
Endometrial epithelium is the presumed tissue of origin for both eutopic and endometriosis-derived clear cell and endometrioid carcinomas. We had previously hypothesized that the morphological, biological and clinical differences between these carcinomas are due to histotype-specific mutations. Although some mutations and genomic landscape features are more likely to be found in one of these histotypes, we were not able to…
Read More